| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Margin | -92.96% | -62.81% | -46.89% | 5.91% | -1641.33% | -749.81% | -122.72% | -138.46% |
| EBITDA Margin | -89.28% | -60.49% | -45.11% | 6.65% | -1631.68% | -740.56% | -119.43% | -134.76% |
| Net Margin | -80.19% | -53.14% | -17.82% | 4.54% | -1647.98% | -756.35% | -125.02% | -138.29% |
| Current Ratio | 6.64 | 4.67 | 4.72 | 3.18 | 3.81 | 9.45 | 3.48 | 3.33 |
| Quick Ratio | 6.64 | 4.67 | 4.72 | 3.18 | 3.81 | 9.45 | 3.48 | 3.33 |
| Debt / Equity | — | — | — | 0.22 | 0.28 | 0.04 | 0.58 | 0.73 |
| ROE | -30.74% | -33.59% | -10.67% | 3.46% | -89.25% | -18.19% | -100.77% | -159.69% |
| ROA | -24.26% | -23.52% | -6.92% | 2.08% | -51.85% | -15.14% | -31.64% | -49.29% |
| Asset Turnover | 0.30 | 0.44 | 0.39 | 0.46 | 0.03 | 0.02 | 0.25 | 0.36 |
| Book Value / Share | 7.81 | 8.93 | 10.46 | 9.98 | 8.67 | 19.53 | 2.14 | 1.35 |
Arcturus Therapeutics Holdings Inc. is a messenger RNA medicines company focused on developing therapeutics for liver and respiratory rare diseases, as well as infectious disease vaccines. It leverages proprietary LUNAR lipid-mediated delivery and STARR self-amplifying mRNA platforms to advance its pipeline. Key internal programs include ARCT-810 for ornithine transcarbamylase deficiency and ARCT-032, an inhaled mRNA therapy for cystic fibrosis, both in Phase 2 clinical studies targeting severe patient populations. In vaccines, it partners with CSL Seqirus on mRNA candidates for COVID-19, influenza, and other infectious diseases, with KOSTAIVE approved in Japan, the EU, and the UK, generating initial commercial sales through collaborators like Meiji and CSL Seqirus. The company operates in a single business segment encompassing discovery, development, and commercialization of mRNA medicines. Founded in 2013 and headquartered in San Diego, California, Arcturus Therapeutics Holdings Inc. plays a significant role in the biotech sector by pioneering mRNA technologies for rare diseases and partnered vaccine franchises.